In the latest trading session, 1.23 million Sarepta Therapeutics Inc (NASDAQ:SRPT) shares changed hands as the company’s beta touched 0.88. With the company’s most recent per share price at $77.73 changing hands around $4.19 or 5.70% at last look, the market valuation stands at $7.54B. SRPT’s current price is a discount, trading about -122.89% off its 52-week high of $173.25. The share price had its 52-week low at $73.06, which suggests the last value was 6.01% up since then. When we look at Sarepta Therapeutics Inc’s average trading volume, we note the 10-day average is 2.34 million shares, with the 3-month average coming to 1.10 million.
Analysts gave the Sarepta Therapeutics Inc (SRPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.46. If we narrow down to specifics, the data shows that 1 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended SRPT as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Sarepta Therapeutics Inc’s EPS for the current quarter is expected to be 1.38.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Instantly SRPT is in green as seen in intraday trades today. With action -22.09%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -36.07%, with the 5-day performance at -22.09% in the red. However, in the 30-day time frame, Sarepta Therapeutics Inc (NASDAQ:SRPT) is -26.22% down. Looking at the short shares, we see there were 5.06 million shares sold at short interest cover period of 5.83 days.
The consensus price target for the stock as assigned by Wall Street analysts is 182, meaning bulls need an upside of 57.29% from its recent market value. According to analyst projections, SRPT’s forecast low is 165 with 202 as the target high. To hit the forecast high, the stock’s price needs a -159.87% plunge from its current level, while the stock would need to soar -112.27% for it to hit the projected low.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
Year-over-year growth is forecast to reach 64.78% up from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 692.97M. 15 analysts are of the opinion that Sarepta Therapeutics Inc’s revenue for the current quarter will be 764.54M. The company’s revenue for the corresponding quarters a year ago was 413.46M and 362.93M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 67.60%. The estimates for the next quarter sales put growth at 110.66%.
The 2025 estimates are for Sarepta Therapeutics Inc earnings to increase by 385.73%, but the outlook for the next 5-year period is at 92.04% per year.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.41% of Sarepta Therapeutics Inc shares while 92.27% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.53%. There are 92.27% institutions holding the Sarepta Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.9845% of the shares, roughly 10.32 million SRPT shares worth $1.63 billion.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.6133% or 9.04 million shares worth $1.43 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Growth Fund of America Inc and iShares Core S&P Midcap ETF. With 3.16 shares estimated at $245.32 million under it, the former controlled 3.25% of total outstanding shares. On the other hand, iShares Core S&P Midcap ETF held about 3.21% of the shares, roughly 3.12 shares worth around $242.37 million.
